Research view
Switch to patient viewMultiple sclerosis: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Pick a target or a country to narrow the list.
- All targets
- CD20 17
- CD19 10
- PPAR 0
- NLRP3 0
- STAT3 0
- BCMA 13
- BTK 1
- IL-17 0
- NRF2 0
- TNF 0
- AQP4 0
- GLP-1 2
- AMPK 0
- BDNF 1
- AKT 0
- IL-6 0
- mTOR 0
- CD40 0
- JAK 0
- PI3K 0
- STING 0
- TREM2 0
- PD-1 0
- IL-1 0
- IL-4 0
- SIRT1 0
- TLR4 0
- AXL 0
- CGRP 0
- CSF1R 0
- HIF-1 0
- IL-23 0
- VEGF 1
- COX-2 0
- CTLA-4 0
- CXCR4 0
- ERK 0
- HMGB1 0
- HSP90 0
- PD-L1 0
- TYK2 1
- APOE 0
- CCR5 0
- CTNNB1 0
- EGFR 0
- FOXP3 0
- GPX4 0
- IDO1 0
- JNK 0
- PARP 0
- PTEN 0
- TP53 1
- ACE2 0
- APP 0
- BCL-2 0
- BRD4 0
- C9orf72 0
- CDK4/6 0
- G6PD 0
- HDAC 0
Running research funding
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
NIH NIAID · F31
Dysregulation of Aging Regulatory T-Cell Response in Autoimmune Disease
U.S. Department of Veterans Affairs · IK2
Remotely administered tDCS to improve cognitive function in Veterans with mTBI and PTSD
U.S. Department of Veterans Affairs · I01
Targeting Blood Retinal Barrier Dysfunction in Multiple Sclerosis
NIH NIAID · F31
Genetic and cellular mechanisms underlying resistance to gammaherpesvirus infection
NIH NINDS · R01
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF
European Commission (Horizon Europe) · HORIZON-ERC
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Molecular regulation of the axon–myelin interface in development and repair (MInDRe)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-ERC
Targeting myeloid cell states, actions and interactions in neuroinflammation (TACO)
10 of 663 running projects, newest first. Listed amounts together: US$294.6m + €130.5m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Withdrawn
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
“No participants.”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
No trial in this view states that it shares participant data.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 16
- Mendelian Randomization Analysis 66
- CRISPR-Cas Systems 3
- Gene Expression Profiling 39
- Sequence Analysis, RNA 6
- Whole Genome Sequencing 1
- Exome Sequencing 3
- Proteomics 34
- Metabolomics 21
- Mass Spectrometry 12
- Flow Cytometry 29
- Immunohistochemistry 10
- Xenograft Model Antitumor Assays 2
- Positron-Emission Tomography 29
- Magnetic Resonance Imaging 570
- Machine Learning 43
- Deep Learning 33
- Cohort Studies 183
- Genome-Wide Association Study 84
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.